Literature DB >> 34092483

A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.

Daniel M Geynisman1, Jodi K Maranchie2, Mark W Ball3, Gennady Bratslavsky4, Eric A Singer5.   

Abstract

The diagnosis, evaluation and management of patients with renal cell carcinoma has transformed in the 21st century. Utilizing biological discoveries and technological advances, the field has moved from blunt surgical and largely ineffective medical treatments, to nuanced and fine-tuned approaches based on biology, extent of disease and patient preferences. In this review we will summarize the last 25 years of progress in kidney cancer.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kidney cancer; Molecular biology; Nephrectomy; Renal cell carcinoma; Systemic therapy

Mesh：

Year:  2021        PMID： 34092483      PMCID： PMC9030590          DOI： 10.1016/j.urolonc.2021.04.038

Source DB:  PubMed          Journal:  Urol Oncol        ISSN： 1078-1439            Impact factor:   2.954


  141 in total

1.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Authors:  Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester
Journal:  Eur Urol       Date:  2010-12-22       Impact factor: 20.096

2.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

3.  Percutaneous renal mass biopsy: historical perspective, current status, and future considerations.

Authors:  Brittney H Cotta; Margaret F Meagher; Aaron Bradshaw; Stephen T Ryan; Gerant Rivera-Sanfeliz; Ithaar H Derweesh
Journal:  Expert Rev Anticancer Ther       Date:  2019-02-20       Impact factor: 4.512

4.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

5.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

6.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

7.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

8.  Renal cell cancer stage migration: analysis of the National Cancer Data Base.

Authors:  Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

9.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

10.  Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.

Authors:  Robert L Grubb; Michael E Franks; Jorge Toro; Lindsay Middelton; Lynda Choyke; Sarah Fowler; Carlos Torres-Cabala; Gladys M Glenn; Peter Choyke; Maria J Merino; Berton Zbar; Peter A Pinto; Ramaprasad Srinivasan; Jonathan A Coleman; W Marston Linehan
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450
View more
  4 in total

Review 1.  New Paradigms for Cytoreductive Nephrectomy.

Authors:  Benjamin J Lichtbroun; Arnav Srivastava; Sai Krishnaraya Doppalapudi; Kevin Chua; Eric A Singer
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

2.  Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma.

Authors:  Luke J Nelson; Kyleen E Castro; Binzhi Xu; Junyi Li; Nguyen B Dinh; Jordan M Thompson; Jordan Woytash; Kevin R Kipp; Olga V Razorenova
Journal:  Cell Cycle       Date:  2022-03-04       Impact factor: 5.173

3.  Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature.

Authors:  Ellen M Cahill; Alexandra Tabakin; Brian Shinder; Mark Bramwit; Biren Saraiya; Xinyang Xu; Cristo G Salazar; Zhongren Zhou; Eric A Singer
Journal:  J Kidney Cancer VHL       Date:  2022-05-25

Review 4.  Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Kevin K Zarrabi; Oladimeji Lanade; Daniel M Geynisman
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.